TY - JOUR
T1 - Effect of Migraine on Pregnancy Planning
T2 - Insights From the American Registry for Migraine Research
AU - Ishii, Ryotaro
AU - Schwedt, Todd J.
AU - Kim, Soo Kyoung
AU - Dumkrieger, Gina
AU - Chong, Catherine D.
AU - Dodick, David W.
N1 - Funding Information:
Potential Competing Interests: Dr Schwedt has served as a consultant for Alder, Allergan, Amgen, Avanir, Biohaven, Cipla, Click Therapeutics, Dr. Reddy’s, Eli Lilly, Equinox, Ipsen Bioscience, Nocira, Novartis, Salvia, Teva, Xoc Pharmaceuticals, and Weber & Weber. He has stock options in Aural Analytics, Nocira, and Second Opinion. He has received research funding from Amgen , American Migraine Foundation , Arizona State University , Henry Jackson Foundation , the National Institutes of Health , Patient-Centered Outcomes Research Institute , and the U.S. Department of Defense . He serves on the boards of directors of the American Headache Society and the International Headache Society. Dr Chong receives research funding from Amgen , Arizona State University , the National Institutes of Health , and the U.S. Department of Defens e and personal compensation from Amgen. Dr Dodick receives personal fees from Amgen, AEON, the Association of Translational Medicine, University Health Network, Daniel Edelman Inc., Autonomic Technologies, Axsome, Allergan, Alder BioPharmaceuticals, Biohaven, Charleston Laboratories, Clexio, Dr Reddy’s Laboratories/Promius, Electrocore LLC, Eli Lilly, eNeura, Neurolief, Novartis, Ipsen, Impel, Satsuma, Supernus, Sun Pharma (India), Theranica, Teva, Vedanta, WL Gore, Nocira, PSL Group Services, XoC, Zosano, ZP Opco, Foresite Capital, Oppenheimer; Upjohn (Division of Pfizer), Pieris, Revance, Equinox, Salvia, and Amzak Health. He has received speaking fees from Eli Lilly, Novartis Canada, Amgen, and Lundbeck and CME fees or royalty payments from HealthLogix, Medicom Worldwide, MedLogix Communications, Mednet, Miller Medical, PeerView, WebMD Health/Medscape, Chameleon, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket, Global Scientific Communications, Global Life Sciences, Global Access Meetings, Catamount, UpToDate (Elsevier), Oxford University Press, Cambridge University Press, and Wolters Kluwer Health. He has stock options in Precon Health, Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, Epien, Nocira, Matterhorn, Ontologics, and King-Devick Technologies. He serves as a consultant without fee for Aural Analytics, Healint, Second Opinion/Mobile Health, and Epien and on the boards of directors of Precon Health, Epien, Matterhorn, Ontologics, and King-Devick Technologies. He owns a patent (without fee) 17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis. He has received research funding from American Migraine Foundation , the U.S. Department of Defense , Patient Centered Outcomes Research Institute, and Henry M. Jackson Foundation and professional society fees or reimbursement for travel from the American Academy of Neurology, American Brain Foundation, American Headache Society, American Migraine Foundation, International Headache Society, and Canadian Headache Society. The other authors report no competing interests.
Funding Information:
Potential Competing Interests: Dr Schwedt has served as a consultant for Alder, Allergan, Amgen, Avanir, Biohaven, Cipla, Click Therapeutics, Dr. Reddy's, Eli Lilly, Equinox, Ipsen Bioscience, Nocira, Novartis, Salvia, Teva, Xoc Pharmaceuticals, and Weber & Weber. He has stock options in Aural Analytics, Nocira, and Second Opinion. He has received research funding from Amgen, American Migraine Foundation, Arizona State University, Henry Jackson Foundation, the National Institutes of Health, Patient-Centered Outcomes Research Institute, and the U.S. Department of Defense. He serves on the boards of directors of the American Headache Society and the International Headache Society. Dr Chong receives research funding from Amgen, Arizona State University, the National Institutes of Health, and the U.S. Department of Defense and personal compensation from Amgen. Dr Dodick receives personal fees from Amgen, AEON, the Association of Translational Medicine, University Health Network, Daniel Edelman Inc., Autonomic Technologies, Axsome, Allergan, Alder BioPharmaceuticals, Biohaven, Charleston Laboratories, Clexio, Dr Reddy's Laboratories/Promius, Electrocore LLC, Eli Lilly, eNeura, Neurolief, Novartis, Ipsen, Impel, Satsuma, Supernus, Sun Pharma (India), Theranica, Teva, Vedanta, WL Gore, Nocira, PSL Group Services, XoC, Zosano, ZP Opco, Foresite Capital, Oppenheimer; Upjohn (Division of Pfizer), Pieris, Revance, Equinox, Salvia, and Amzak Health. He has received speaking fees from Eli Lilly, Novartis Canada, Amgen, and Lundbeck and CME fees or royalty payments from HealthLogix, Medicom Worldwide, MedLogix Communications, Mednet, Miller Medical, PeerView, WebMD Health/Medscape, Chameleon, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket, Global Scientific Communications, Global Life Sciences, Global Access Meetings, Catamount, UpToDate (Elsevier), Oxford University Press, Cambridge University Press, and Wolters Kluwer Health. He has stock options in Precon Health, Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, Epien, Nocira, Matterhorn, Ontologics, and King-Devick Technologies. He serves as a consultant without fee for Aural Analytics, Healint, Second Opinion/Mobile Health, and Epien and on the boards of directors of Precon Health, Epien, Matterhorn, Ontologics, and King-Devick Technologies. He owns a patent (without fee) 17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis. He has received research funding from American Migraine Foundation, the U.S. Department of Defense, Patient Centered Outcomes Research Institute, and Henry M. Jackson Foundation and professional society fees or reimbursement for travel from the American Academy of Neurology, American Brain Foundation, American Headache Society, American Migraine Foundation, International Headache Society, and Canadian Headache Society. The other authors report no competing interests.
Publisher Copyright:
© 2020 Mayo Foundation for Medical Education and Research
PY - 2020/10
Y1 - 2020/10
N2 - Objective: To evaluate the effect of migraine on women's pregnancy plans. Patients and Methods: Participants were enrolled in the American Registry for Migraine Research, an observational study that recruits patients from headache specialty clinics across the United States. Data for this analysis were collected via patient-completed questionnaires completed from February 1, 2016, through September 23, 2019. Participants were adult women with migraine who answered the American Registry for Migraine Research family planning questions. Results: Of 607 women, 19.9% (n=121) avoided pregnancy because of migraine. Compared with women who did not avoid pregnancy, those who did were younger (37.5±9.2 years vs 47.2±13.3 years; P<.001), had fewer children (0.8±1.1 vs 1.5±1.5; P<.001), and were more likely to have chronic migraine (n=99 [81.8%] vs n=341 [70.2%]; P=.012) and menstrually associated migraine (n=5 [4.1%] vs n=5[1.0%]; P=.031). Women who avoided pregnancy believed that their migraine would be worse during pregnancy (n=87[72.5%]), disability caused by migraine would make pregnancy difficult (n=82[68.3%]), the migraine medications they take would negatively affect their child's development (n=92[76.0%]), and migraine would cause the baby to have abnormalities at birth (n=17[14.0%]). Conclusion: Migraine effects pregnancy plans of many women, especially of those who are younger and have menstrual migraine and chronic migraine. Women who avoid pregnancy because of migraine believe that migraine will worsen during pregnancy, make their pregnancy difficult, and have negative effects on their child. Study results highlight the importance of educating women with migraine about the relationships between migraine and pregnancy so that informed family planning decisions can be made.
AB - Objective: To evaluate the effect of migraine on women's pregnancy plans. Patients and Methods: Participants were enrolled in the American Registry for Migraine Research, an observational study that recruits patients from headache specialty clinics across the United States. Data for this analysis were collected via patient-completed questionnaires completed from February 1, 2016, through September 23, 2019. Participants were adult women with migraine who answered the American Registry for Migraine Research family planning questions. Results: Of 607 women, 19.9% (n=121) avoided pregnancy because of migraine. Compared with women who did not avoid pregnancy, those who did were younger (37.5±9.2 years vs 47.2±13.3 years; P<.001), had fewer children (0.8±1.1 vs 1.5±1.5; P<.001), and were more likely to have chronic migraine (n=99 [81.8%] vs n=341 [70.2%]; P=.012) and menstrually associated migraine (n=5 [4.1%] vs n=5[1.0%]; P=.031). Women who avoided pregnancy believed that their migraine would be worse during pregnancy (n=87[72.5%]), disability caused by migraine would make pregnancy difficult (n=82[68.3%]), the migraine medications they take would negatively affect their child's development (n=92[76.0%]), and migraine would cause the baby to have abnormalities at birth (n=17[14.0%]). Conclusion: Migraine effects pregnancy plans of many women, especially of those who are younger and have menstrual migraine and chronic migraine. Women who avoid pregnancy because of migraine believe that migraine will worsen during pregnancy, make their pregnancy difficult, and have negative effects on their child. Study results highlight the importance of educating women with migraine about the relationships between migraine and pregnancy so that informed family planning decisions can be made.
UR - http://www.scopus.com/inward/record.url?scp=85091638063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091638063&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2020.06.053
DO - 10.1016/j.mayocp.2020.06.053
M3 - Article
C2 - 32948327
AN - SCOPUS:85091638063
VL - 95
SP - 2079
EP - 2089
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 10
ER -